Rakshamani Tripathi

Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition

MAPK inhibitors (MAPKi) are important treatment options for some patients with metastatic melanoma; however, resistance inevitably develops in the vast majority of cases (>70%). Here, using immune-proficient mouse models, single-cell RNA sequencing, flow cytometry, and datasets from patients treated with MAPKi, we demo...